OncoMatch/Clinical Trials/NCT06707493
Ivosidenib as Post-HSCT Maintenance for AML
Is NCT06707493 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Ivosidenib for idh1 mutation.
Treatment: Ivosidenib — This is a Phase 2 study of the study drug, ivosidenib (a mutant IDH1 inhibitor), compared to placebo, given to patients with IDH1-mutant acute myeloid leukemia (AML) after hematopoietic stem cell transplantation (HCT).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Cancer type
Acute Myeloid Leukemia
Biomarker criteria
Required: IDH1 r132 mutation
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Must have received: hematopoietic stem cell transplant — allogeneic
Will undergo allogeneic hematopoietic stem cell transplantation (HSCT) for their malignancy.
Cannot have received: allogeneic hematopoietic stem cell transplant
Prior allogeneic hematopoietic stem cell transplants.
Lab requirements
Blood counts
Absolute neutrophil count ≥ 1000/µL without growth factor support in the previous 7 days; Platelet count ≥ 50,000/µL without transfusional support in the previous 7 days
Kidney function
Calculated creatinine clearance ≥ 40 mL/min (Cockcroft-Gault formula)
Liver function
AST (SGOT), ALT (SGPT) and Alkaline phosphatase < 3x institutional upper limit of normal (ULN); Direct bilirubin < 2.0 mg/dL
Cardiac function
LVEF must be equal to or greater than 40%, as measured by MUGA scan or echocardiogram
Participants must have normal organ and marrow function as defined below: - Absolute neutrophil count ≥ 1000/µL without growth factor support (e.g. GCSF) in the previous 7 days. - Platelet count ≥ 50,000/µL without transfusional support in the previous 7 days. - AST (SGOT), ALT (SGPT) and Alkaline phosphatase < 3x institutional upper limit of normal (ULN) - Direct bilirubin < 2.0 mg/dL - Calculated creatinine clearance ≥ 40 mL/min (Cockcroft-Gault formula) LVEF must be equal to or greater than 40%, as measured by MUGA scan or echocardiogram
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Massachusetts General Hospital · Boston, Massachusetts
- Dana Farber Cancer Institute · Boston, Massachusetts
- Froedtert Hospital & the Medical College of Wisconsin · Milwaukee, Wisconsin
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06707493 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior allogeneic hematopoietic stem cell transplant disqualifies patients from enrollment.
Does this trial require IDH1?
Yes, IDH1 r132 mutation is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages